Renal cell carcinoma (RCC) affects nearly 300,000 worldwide each year and is responsible for nearly 100,000 deaths annually. Clear cell RCC (ccRCC), the most common form of sporadic RCC, often presents with synchronous metastatic disease that correlates with poor prognosis. Complete loss of the chromosome 3p-encoded VHL gene by combined loss of chromosome 3p plus mutation or hypermethylation of the remaining copy occurs in 90% of ccRCC (TCGA, 2013; Sato et al., 2013) . In addition, inherited VHL mutations are pathognomonic for the multi-focal ccRCC predisposing von Hippel-Lindau (VHL) syndrome (Linehan et al., 2010) . In this issue of Cell, a series of three articles present a technical and analytical tour de force study of the origin, evolution, and route to metastasis of clear cell renal carcinoma to an extent that may not yet have been achieved in any other cancer to date (Mitchell et al., 2018; Turajlic et al. 2018a Turajlic et al. , 2018b . Recent studies from the same group described the profound intratumoral genetic heterogeneity in sporadic primary ccRCC tumors characterized by a small number of truncal or clonal alterations (Gerlinger et al., 2012 (Gerlinger et al., , 2014 . Most somatic alterations in ccRCC were found to be subclonal and present in varying degrees throughout the tumor, illustrating the inability of single-sampling techniques to identify the full spectrum of genetic alterations. In the current studies, the authors analyzed a multicenter, prospective longitudinal cohort of patients with ccRCC, tracking RCC evolution through therapy (TRACERx Renal, clinical trials no. NCT03226886), providing in-depth understanding of the underlying genetic alterations, as well as tumor heterogeneity, in both primary and metastatic tumors.
First, primary tumor samples from a third of the patient cohort were subjected to whole-genome sequencing (WGS) for detailed molecular profiling (Mitchell et al., 2018) . Campbell and colleagues evaluated driver mutations in non-coding regions of the genome and identified new 5 0 UTR TERT mutations, in addition to previously reported oncogenic alterations in the promoter (Huang et al., 2013) . The 5 0 UTR mutations were confirmed in a validation cohort and clustered around an E-box sequence capable of binding the MYC-MAX-MAD1 family of proteins. Non-coding mutations of TERT, which were both clonal and subclonal, correlated with longer tumor telomere lengths. Further evaluation of chromosomal translocations in relation to copy number alterations confirmed the loss of chromosome 3p as a nearly universal event in ccRCC, with gain of chromosome 5q the second most common event. Unbalanced translocations of chromosomes 3 and 5, which simultaneously result in chromosome 3p loss and 5q gain, were found to be the most frequent mechanism for chromosome 3p loss (43%) and, in most cases, resulted from multiple (5-30) focally clustered rearrangements, characteristic of a chromothripsis event. The t(3;5) chromothripsis events were confirmed in the TCGA ccRCC cohort and in an additional set of 40 renal tumors from VHL syndrome patients (TCGA, 2013; Fei et al., 2016) . Assuming that (1) the rate of somatic mutation in kidney cells is constant throughout life, (2) that any somatic mutations present on both duplicated chromosomes 5q must have been present before duplication, and finally (3) that any mutations present on a single duplicated chromosome 5q must have occurred after duplication, the authors concluded that t(3;5) translocation is the earliest tumorigenic event in ccRCC and occurs within the first two decades of life. The authors reasoned that this earliest event would be predicted to produce a small pool of tumor-initiating cells, which would then require time to acquire the necessary additional genetic alterations, such as mutation of the remaining wild-type VHL gene, to form full-blown ccRCC (Figure 1 ). These findings elucidated the molecular path underlying previously held beliefs that ccRCC takes decades to evolve and correlates with early disease onset in VHL patients, who develop bilateral, multifocal renal tumors decades before the average onset of sporadic renal tumors. The authors further proposed that this small population of tumor-initiating cells may present a promising target for prevention of disease progression.
Following the in-depth WGS molecular profiling, 1,206 regions within 101 primary ccRCC tumors were subjected to multi-regional exome sequencing for a comprehensive depiction of the genetic and clonal evolution features of the cohort (Turajlic et al., 2018b) . This exhaustive analysis revealed a higher frequency of mutations in ccRCC driver genes and driver somatic copy number alterations (SCNAs) within the tumors compared to previous single-region sequencing analyses, including known prognostic markers such as BAP1 mutation and chromosome 9p21.3 loss.
Parallel evolution of both driver mutations, such as BAP1, SETD2, and PTEN, and driver SCNAs, such as chromosome 14q loss, highlighted the importance of these alterations in tumor progression and their relevance as potential precision therapy targets. Moreover, Swanton and colleagues evaluated the order in which key driver events occur in tumor evolution and identified seven evolutionary subtypes (Figure 1 ). Two subtypes defined by either multiple clonal drivers or the gain of BAP1 mutation were characterized by lower levels of intratumor heterogeneity (ITH) and higher levels of genomic instability that correlated with a more aggressive phenotype. Notably, a rare subtype defined by a lack of driver alterations, including no VHL functional loss, was found to be associated with increased ITH, genomic instability and higher stage and grade of tumors. Increased ITH and genomic instability each individually negatively influenced progression-free survival, while the combination of both low ITH and high genomic instability correlated with poorest overall survival. When the authors addressed the critical question of how many regions need to be sampled to provide an adequate reflection of subclonal alteration, they found that four samplings would capture R75% of variants in low-ITH cases, whereas in the high-ITH cases, eight was sufficient to cover similar proportion of variants. The calculation highlighted the importance of multiple-site sampling for not only precisely characterizing the evolutionary nature of tumor masses, but also guiding clinicians toward precision clinical disease management.
In the final paper in this series, Swanton and colleagues carried out a comparative study by multi-regional exomesequencing analysis of 336 metastatic biopsies and 589 primary renal tumor biopsies from 100 ccRCC patients Early in the life of a patient, a normal renal epithelial cell acquires an unbalanced translocation between chromosomes 3 (green) and 5 (red) through a chromothripsis event during cell division that results in gained regions of chromosome 5q and lost regions of chromosome 3p. This cell propagates into a small pool of cells with the potential to become ccRCC tumors (yellow). Multi-regional sequencing of ccRCC tumors demonstrated the clonal and subclonal genetic alterations gained during tumorigenesis and tumor proliferation that were used to define 7 evolutionary subtypes. The tumor heterogeneity and genomic instability features of each evolutionary subtype are shown, with the three subtypes based on PBRM1 mutation plus either SETD2 mutation, phosphoinositide 3-kinase (PI3K) pathway mutation, or somatic copy number alteration (SCNA) combined. The multiple clonal drivers subtype was defined as tumors with clonal mutations in 2 or more of BAP1, PBRM1, SETD2, or PTEN. ccRCC tumors demonstrating the multiple clonal drivers, BAP1-driven, and VHL wild-type evolutionary subtypes were more likely to show rapid metastatic progression to multiple tissue sites (red), while the multiple PBRM1-driven and VHL monodriver evolutionary subtypes were more likely to have attenuated progression to a solitary metastatic site. (Turajlic et al., 2018a) . Most notably, metastatic sites were found to have significantly fewer subclonal alterations than primary tumors and were found to have few unique clonal or subclonal driver alterations. In the metastatic sites, clonal selection of subclonal primary alterations was found with significant enrichment for chromosome 9p21.3 loss and increased frequency of chromosome 14q loss. Rapid progression to multiple metastatic sites was found to be associated with the multiple clonal drivers and the BAP1-driven evolutionary subtypes with lower tumor heterogeneity and high genomic instability, as well as with the VHL wild-type evolutionary subtype characterized by increased tumor heterogeneity and high genomic instability ( Figure 1 ). Attenuated progression to solitary metastases was associated with the PBRM1-driven evolutionary subtypes with higher primary tumor heterogeneity. The findings raised the possibility that these cases may benefit the most from cytoreductive nephrectomies to minimize the risk of further metastatic seeding from an evolving primary tumor containing clones with variable metastatic potential.
This remarkable series of studies has significantly advanced our understanding of the origin and evolution trajectories of ccRCC tumors, providing a framework that could potentially guide the development of more effective forms of management and therapy for patients affected with localized, locally advanced or advanced ccRCC.
Mechanoreceptors mediate a wide variety of physiological processes, such as hearing, touch, proprioception, and blood flow regulation. It is generally believed that mechanoreceptors are forcegated ion channels. Now, Xu et al. uncover a GPCR that is activated by shear force in endothelial cells of blood vessels.
In addition to neurons, many cell types, such as those in the bone, muscle, kidney, eye, and blood vessels, respond to mechanical stimuli. However, the underlying mechanoreceptors are only beginning to be discovered, especially in mammals.
Progress toward this goal in mammals has been hindered in part by the relatively small number of mechanosensory cells, the difficulty of performing electrophysiological experiments in vivo, and the challenge of reconstituting mechanoreceptor protein complexes in heterologous systems.
What we do know about mechanoreceptors largely comes from work in model organisms such as bacteria, C. elegans, and Drosophila (Katta et al., 2015, Xiao
